17%Marketing, selling and administrative1,652.01,847.5
(11)%Operating income 1,443.61,405.1
3%Net interest income (expense)(16.7)(19.2)Net other income (expense)50.5(26.8)Other income (expense)33.8(46.0)
NMIncome before income taxes1,477.41,359.1
22%Earnings per share – diluted
24%Dividends paid per share
Weighted-average sharesoutstanding (thousands) – diluted
1,116,983(a) The first-quarter 2013 financial statements have been adjusted to eliminate asset impairments, restructuring and other special charges totaling $21.7 million (pretax), or $0.01 per share (after-tax), related to severance costs from actions the company is taking, primarily outside the U.S., to reduce its cost structure and global workforce. Additionally, they have been adjusted to eliminate income totaling $495.4 million (pretax), or $0.29 per share (after-tax), related to the transfer of exenatide commercial rights outside the U.S. to Amylin.
(b) The first-quarter 2012 financial statements have been adjusted to eliminate asset impairments, restructuring and other special charges totaling $23.8 million (pretax), or $0.01 per share (after-tax), primarily related to the withdrawal of Xigris.
Refer to: (317) 276-5795 – Mark Taylor (Media)
(317) 655-6874 – Philip Johnson (Investors)
|SOURCE Eli Lilly and Company|
Copyright©2012 PR Newswire.
All rights reserved